Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
On Monday, Cramer said he'll be watching the health care stocks because he expects at least one, and possibly two, big mergers in that group coming soon.
Next, on Tuesday, it's the latest Greek deadline that will be capturing the market's attention. Cramer said he'll also be watching ConAgra Foods (CAG) as activists prod that company into action, and also AeroVironment (AVAV), which has now been supplanted by Ambarella (AMBA) as the go-to name for making money with unmanned drones.
For Thursday, it's the next big, bad, jobs report, news that's sure to bring out all of the Federal Reserve watchers calling for an immediate interest rate hike.
Fortunately, on Friday, the markets will be closed, giving everyone time to digest all of the macro-economic news they received.
Executive Decision: Jim Whitehurst and Frank Calderoni
For his "Executive Decision" segment, Cramer sat down with Jim Whitehurst, president and CEO of Red Hat (RHT), as well as Frank Calderoni, Red Hat's new CFO, formerly from Cisco Systems (CSCO). Shares of Red Hat have risen 40% over the past 12 months.
Whitehurst said the majority of the world's equity markets run on Red Hat software, including the New York Stock Exchange. That's because of Red Hat's speed and security features.
When asked about his move from Cisco to Red Hat, Calderoni explained Cisco has always had a great partnership with Red Hat, and the company was a logical choice for his next opportunity. Both Red Hat and Cisco have a lot of synergies when it comes to building the cloud-based systems companies are craving.
Whitehurst also touted Red Hat's subscription model as a big plus for his company, saying Red Hat has both a high renewal rate and is always innovating with new services that customers can sign up for.
Running With Nike
What should investors make of the fabulous quarter posted by Nike (NKE) and the abysmal one posted by Micron Technology (MU)? Cramer said the markets got this one right because Micron fell to a 52-week low while Nike soared to all-time highs.
Nike's simply doing everything right, Cramer said, pouring tons on money into research and development and delivering innovative products that customers are clamoring for around the globe. Meanwhile, Micron still largely makes DRAM memory chips, and there's no shortage of those.
While customers are willing to pay up for the latest pair of Nike sneakers, PC prices continue to slide, taking the values of the component makers with them.
"The markets got this one right," Cramer reiterated. Nike is heading only higher while Micron will continue to slide into obscurity.
Executive Decision: Glenn Lyon
In his second "Executive Decision" segment, Cramer spoke with Glenn Lyon, chairman and CEO of Finish Line (FINL), the athletic apparel chain with 1,030 stores that just delivered a 6-cents-a-share earnings beat on better-than-expected revenue that jumped 9.1% year over year.
Lyon said that Finish Line is always making bets on which merchandise customers will want nine months in advance and sometimes, he admitted, they get it wrong. But after a weak start of the year, they're back and moving in the right direction.
Additionally, Lyon said Finish Line continues to invest in technology to offer its customers an omni-channel experience where they can order from anywhere they are. Finish Line also continues to excel with its store-within-a-store concept inside of Macy's (M).
Cramer said the Finish Line story extends well beyond a single quarter and he remains bullish on the stock because it is the least expensive in the group.
In his "Homework" segment, Cramer followed up on a few stocks that stumped him during previous shows. He explained that Real Industries (RELY) is what's known as a SPAC, or special purpose acquisition company, one that is too risky for him.
Cramer said that Spark Therapeutics (ONCE) has a promising Phase III trial and impressive leadership but the stock is too volatile for his liking.
When asked about Eagle Pharmaceuticals (EGRX), another biotech company, which has soared over 424% so far in 2015, Cramer said the positives are most certainly baked into share price but a takeover bid is possible given its promising pipeline.
Finally, Cramer noted that Lion Biotechnology (LBIO), which is working in the cancer immunotherapy area, is also too risky and amounts to a lottery ticket for shareholders.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.